Genprex Appoints Shannon Inman as Vice President of Global Clinical Operations
April 21, 2020
Proven executive with clinical operations expertise to guide Company’s clinical programs with gene therapies
AUSTIN, Texas — (April 21, 2020) — Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of Shannon Inman as Vice President of Global Clinical Operations. In this new position, Ms. Inman will lead in defining clinical developmental strategies, clinical protocol design, study conduct, and managing risk assessment. These clinical trials include those with the Company’s lead drug candidate, Oncoprex™, for non-small cell lung cancer (NSCLC), which recently received Fast Track Designation for its combination with osimertinib, AstraZeneca’s first-line targeted EGFR TKI drug Tagrisso®.
“Genprex continues to strengthen its leadership team with the appointment of an accomplished executive to drive the launch of key clinical trials,” said Rodney Varner, Chairman and Chief Executive Officer of Genprex. “Ms. Inman brings a wealth of experience in the pharmaceutical industry, having successfully directed a number of development programs in both large and small biotechnology companies and top tier academic institutions. She will be instrumental in continuing to build the long-term value of our gene therapies. With the addition of our second investigational gene therapy asset addressing the unmet medical need of people suffering from diabetes, I’m excited about building the necessary infrastructure to facilitate our growth.”
Prior to Genprex, Ms. Inman served in several clinical operations positions, most recently as Vice President of Global Clinical Operations at Cell Medica (now Kuur Therapeutics), providing strategic and operational leadership for gene and cell therapy clinical-stage programs, overseeing global clinical operations teams and multi-center global clinical trials targeting various oncology indications. Before that, Ms. Inman held positions of increasing responsibility at Opexa Therapeutics, focusing on T-cell therapies. She has also held various positions at Baylor College of Medicine’s Center for Cell and Gene Therapy working in regulatory, project management, and data management roles since the department’s inception.
Ms. Inman received her Bachelors of Science at Texas A&M in biomedical science. She is a Certified Clinical Research Professional (CCRP), is involved in numerous professional associations, and is a co-author of seven publications.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding our possible commercial partnerships and regarding our financial resources. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of Oncoprex™, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including our gene therapy in diabetes, advance into clinical trials; our ability to enter into strategic partnerships and the success of those partnerships; the timing and success of obtaining FDA approval of Oncoprex™ and our other potential product candidates; and the extent and duration of the current and future economic and pandemic related challenges we may face. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.